Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X:
“Pancreatic cancer clinical trials in AACR24:
- CT022 – Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer. mKRAS-specific T cell response induced.
- CT134 – Neoadjuvant/adjuvant GM-CSF-secreting allogeneic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4. Safe and significantly increased activated CD8+ T cells.
- CT025 – Personalized RNA neoantigen vaccines (autogenous cerumen). Induces polyfunctional CD8+ T effector cells of significant longevity, substantial magnitude, and durable function.
- CT031 -Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline resectable pancreas cancer. Favorable rates of R0 resection, PFS, and OS.
- CT016 -Entinostat plus nivolumab. Immunomodulation of myeloid cell populations
- CT080 / 7 -Devimistat plus chemoradiation in inoperable pancreatic cancer. Safe and well tolerated, trial in progress.
- CT106 / 14 – Paclitaxel-eluting PTM-101 film in borderline resectable or locally advanced pancreatic cancer. Surgically feasible, safe, resulted in no systemic paclitaxel exposure, and caused a tumor size reduction.
- CT107 / 15 – Lymph node targeted mKRAS-specific amphiphile vaccine. Durable immunogenicity.
- Siltuximab plus spartalizumab in advanced pancreatic cancer. Safe but did not elicit responses.
- CT214 / 14 – Paricalcitol plus chemotherapy in metastatic pancreatic cancer. Limited clinical benefit.
- Minnelid in chemotherapy-refractory metastatic pancreatic cancer. Safe but did not elicit responses.
- Narmafotinib plus gemcitabine and nab-paclitaxel as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial). Safe and PR in 47% of patients.”
Source: Erman Akkus/X